UA114706C2 - Композиція для лікування нервових розладів - Google Patents

Композиція для лікування нервових розладів

Info

Publication number
UA114706C2
UA114706C2 UAA201312638A UAA201312638A UA114706C2 UA 114706 C2 UA114706 C2 UA 114706C2 UA A201312638 A UAA201312638 A UA A201312638A UA A201312638 A UAA201312638 A UA A201312638A UA 114706 C2 UA114706 C2 UA 114706C2
Authority
UA
Ukraine
Prior art keywords
compositions
treatment
neurologic disorders
vitamin
mufas
Prior art date
Application number
UAA201312638A
Other languages
English (en)
Inventor
Панцаріс Маріос
Патрікіос Іоанніс
Лукаідіс Георгіос
Original Assignee
Палупа Медікал Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46275907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA114706(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Палупа Медікал Лтд. filed Critical Палупа Медікал Лтд.
Publication of UA114706C2 publication Critical patent/UA114706C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується рідкої пероральної фармацевтичної композиції, що містить довголанцюжкову фракцію поліненасиченої жирної кислоти (PUFA), яка містить ейкозапентаєнову кислоту (EPA), докозагексаєнову кислоту (DHA), лінолеву кислоту (LA) і гамму-ліноленову кислоту (GLA), де співвідношення DHA:EPA складає від приблизно 2:1 до приблизно 5:1 (мас./мас.), одну або декілька інших PUFA омега-3 і одну або декілька мононенасичених жирних кислот (MUFA) і терапевтично ефективну кількість гамма-токоферолу, де гамма-токоферол присутній в кількості від 100 до 3000 мг з розрахунку на щоденну дозу композиції і де введення терапевтично ефективної кількості композиції пацієнту, який страждає на нейродегенеративне захворювання, приводить до зниження тяжкості захворювання.
UAA201312638A 2011-03-29 2012-03-28 Композиція для лікування нервових розладів UA114706C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469081P 2011-03-29 2011-03-29
PCT/IB2012/000824 WO2012131493A1 (en) 2011-03-29 2012-03-28 Compositions for the treatment of neurologic disorders

Publications (1)

Publication Number Publication Date
UA114706C2 true UA114706C2 (uk) 2017-07-25

Family

ID=46275907

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201312638A UA114706C2 (uk) 2011-03-29 2012-03-28 Композиція для лікування нервових розладів

Country Status (21)

Country Link
US (2) US20120252888A1 (uk)
EP (1) EP2691086B1 (uk)
JP (1) JP6092843B2 (uk)
CN (1) CN104010634B (uk)
AU (1) AU2012235869B2 (uk)
BR (1) BR112013025088B1 (uk)
CA (1) CA2831506C (uk)
CY (1) CY1117828T1 (uk)
DK (1) DK2691086T3 (uk)
EA (1) EA025232B1 (uk)
ES (1) ES2585066T3 (uk)
GE (1) GEP201606568B (uk)
HK (1) HK1194665A1 (uk)
HR (1) HRP20160939T1 (uk)
HU (1) HUE028065T2 (uk)
IL (1) IL228541A (uk)
MX (1) MX2013011295A (uk)
PL (1) PL2691086T3 (uk)
UA (1) UA114706C2 (uk)
WO (1) WO2012131493A1 (uk)
ZA (1) ZA201307256B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
ITMI20130354A1 (it) * 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
WO2015073515A1 (en) * 2013-11-12 2015-05-21 Abbott Laboratories Uses of nutritional compositions including natural vitamin e, and polyunsaturated fatty acid
CN106687113B (zh) 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法
BR112017009678A2 (pt) * 2014-11-07 2018-01-23 Kocheri Paul Thomson composição optimizada de nutrientes de ácidos graxos e método de preparação da mesma
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
AR102008A1 (es) * 2015-09-24 2017-01-25 Brix S R L Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas
CA3042592A1 (en) * 2016-11-04 2018-05-11 Immd Sp. Zo.O Inteligent delivery of ingested and absorbed molecules
CN109125311A (zh) * 2018-06-26 2019-01-04 东南大学 预防或治疗阿尔茨海默症的药物组合物及其应用
JP7075869B2 (ja) 2018-10-29 2022-05-26 昭和電工株式会社 ヒートシンクの製造方法
EP4384157A1 (en) * 2021-08-09 2024-06-19 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601399D0 (en) * 1986-01-21 1986-02-26 Delta Iota Ltd Information transmission/processing
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JP3283274B2 (ja) * 1991-06-15 2002-05-20 サントリー株式会社 新規組成物
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US7045683B2 (en) 2001-05-04 2006-05-16 Abbott Laboratories Δ4-desaturase genes and uses thereof
PT1390025E (pt) * 2001-05-30 2005-08-31 Laxdale Ltd Utilizacao de coenzima q (ubiquinona) e acido eicosapentaenoico (epa) para o tratamento de linfoma nao de hodgkin e de distubios psiquiatricos ou neurologicos
DE60220415T2 (de) 2001-07-27 2008-02-14 Neptune Technologies & Bioressources Inc., Laval Flavonoide und mehrfach ungesättigte fettsäuren enthaltende natürliche phospholipide maritimen ursprungs sowie deren anwendungen
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US20050080109A1 (en) 2003-10-09 2005-04-14 Papas Andreas M. Gamma-tocopherol and gamma-tocotrienol therapy for multiple sclerosis
CN101346138B (zh) * 2005-12-21 2013-03-13 布鲁迪科技有限公司 Dha、epa或dha衍生的epa用于治疗细胞氧化损伤相关疾病的用途
US20090196862A1 (en) * 2008-01-22 2009-08-06 William Davis High dosage Vitamin D
JP2010155799A (ja) * 2008-12-26 2010-07-15 Fujifilm Corp 粉末組成物及びそれを含む食品
JP5872453B2 (ja) * 2009-04-17 2016-03-01 ナタク ファルマ エセ．エレ． フィタン酸含量が低く、ω−３脂肪酸に富む組成物

Also Published As

Publication number Publication date
HK1194665A1 (zh) 2014-10-24
EP2691086A1 (en) 2014-02-05
CN104010634A (zh) 2014-08-27
EA201391407A1 (ru) 2014-03-31
AU2012235869A1 (en) 2013-10-17
AU2012235869B2 (en) 2017-04-20
NZ616554A (en) 2015-10-30
CY1117828T1 (el) 2017-05-17
EA025232B1 (ru) 2016-12-30
CA2831506C (en) 2019-07-09
BR112013025088B1 (pt) 2021-12-14
GEP201606568B (en) 2016-11-10
WO2012131493A1 (en) 2012-10-04
PL2691086T3 (pl) 2016-12-30
BR112013025088A2 (pt) 2017-02-14
EP2691086B1 (en) 2016-04-27
US20190343774A1 (en) 2019-11-14
CN104010634B (zh) 2017-06-09
JP2014512351A (ja) 2014-05-22
ZA201307256B (en) 2014-12-23
US20120252888A1 (en) 2012-10-04
IL228541A (en) 2017-11-30
DK2691086T3 (en) 2016-08-15
IL228541A0 (en) 2013-12-31
HRP20160939T1 (hr) 2016-10-07
HUE028065T2 (en) 2016-11-28
ES2585066T3 (es) 2016-10-03
JP6092843B2 (ja) 2017-03-08
CA2831506A1 (en) 2012-10-04
MX2013011295A (es) 2014-11-10

Similar Documents

Publication Publication Date Title
UA114706C2 (uk) Композиція для лікування нервових розладів
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
NZ627980A (en) Pharmaceutical compositions containing dimethyl fumarate
MY160249A (en) Fatty acid fumarate derivatives and their uses
PH12015500106B1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX2015014666A (es) Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
WO2012148926A3 (en) Neurodegenerative disorders and muscle diseases implicating pufas
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2016014509A (es) Formulacion de vitamina soluble en grasa.
EP2560633A4 (en) INTRAVENOUS COMPOSITIONS OF OMEGA-3 FATTY ACIDS AND METHOD OF USE
MY191884A (en) Oil purification process
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
IN2014DN05811A (uk)
WO2013100718A3 (ko) 라저스트로에미아 오바리폴리아 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 질환 또는 천식의 예방 또는 치료용 약학적 조성물
MX2015012771A (es) Procedimiento de tratamiento de la deficiencia de vitamina b12.
EP3538121A4 (en) SYNERGISTIC NUTRITIONAL COMPOSITIONS TO IMPROVE BRAIN HEALTH
EP3270883A4 (en) Scalable vitamin composition unit dosage for the treatment of fat-soluble vitamin deficiencies
EA201790622A1 (ru) Терапевтические и питательные композиции для функциональных нарушений работы пищеварительной системы
GB2530226A (en) Chewable tablet
MX2012014071A (es) Composicion farmaceutica estable para el tratamiento de osteoporosis.
MX2016016118A (es) Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.